Original InvestigationEditorial CommentTaming Immune and Inflammatory Responses to Treat Atherosclerosis∗
Corresponding Author
Key Words
Cited by (0)
Dr. Libby was supported by grants from the National Heart, Lung, and Blood Institute (HL080472) and the RRM Charitable Fund. Dr. Hansson was supported by grants from the Swedish Research Council (grants 6816 and 8703), Swedish Heart-Lung Foundation, the Foundation for Strategic Research, Stockholm County Council, and the European Commission (FP7 projects Athero-Flux and VIA). Dr. Libby’s laboratory has received funding from Novartis; he is an unpaid consultant to Amgen, AstraZeneca, Esperion Therapeutics, Ionis Pharmaceuticals, Sanofi-Regeneron, and XBiotech, Inc.; and a member of the scientific advisory board for Corvidia Therapeutics, Olatec Therapeutics, and Medimmune. Dr. Hansson has been a consultant to Cardiovax, Inc., and Cadila Pharmaceuticals, Inc.
- ∗
Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.